Clinical and Translational Oncology

, Volume 20, Issue 5, pp 647–657 | Cite as

Predicting the cancer burden in Catalonia between 2015 and 2025: the challenge of cancer management in the elderly

  • R. Clèries
  • A. Ameijide
  • R. Marcos-Gragera
  • L. Pareja
  • M. Carulla
  • M.-L. Vilardell
  • L. Esteban
  • M. Buxó
  • J.-A. Espinàs
  • A. Puigdefàbregas
  • J. Ribes
  • A. Izquierdo
  • J. Galceran
  • J. M. Borrás
Research Article

Abstract

Background

Developing effective cancer control programmes requires information on the future cancer burden in an ageing population. In our study we predicted the burden of cancer in Catalonia from 2015 to 2025.

Methods

Bayesian age–period–cohort models were used to predict the burden of cancer from 2015 to 2025 using incidence data from the Girona and Tarragona cancer registries and cancer mortality data from the Catalan mortality registry. Using the Bashir–Estève method, we divided the net change in the number of cases between 2015 and 2025 into changes due to population size (S), cancer risk (R) and age (A) distribution.

Results

By 2025, there will be 21,743 new cancer cases in men (40% aged > 74 years) and 17,268 in women (37% aged > 74 years). More than 40% of the new cases will be diagnosed among population aged 74 and older in prostate, colorectal, lung, bladder, pancreatic and stomach cancers in men, and in colorectal, pancreatic and bladder cancers and leukaemia in women. During 2015–2025, the number of new diagnoses will increase by 5.5% in men (A + R + S = 18.1% − 13.3% + 0.7% = 5.5%) and 11.9% in women (A + R + S = 12.4% − 1.1% + 0.6% = 11.9%). Overall cancer mortality rates will continue to decrease during 2015–2025. Lung cancer will be the most lethal cancer among men (N = 2705) and women (N = 1174).

Conclusions

The increase in the number of cancer cases in Catalonia from 2015 to 2025 will mostly affect the elderly, prompting the need for increased collaboration between geriatricians and oncologists.

Keywords

Cancer Incidence Mortality Projections Ageing Burden 

Notes

Acknowledgements

This work was supported by the Agència d’Avaluació d’Universitats i Recerca (2014SGR0635), and partially supported by Instituto de Salud Carlos III through the Project PI14/01041, co-funded by European Regional Development fund/European Social fund: “investing in your future”.

Compliance with ethical standards

Conflict of interest

The funders had no role in the design of the study, the collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication. The authors state that there are no conflicts of interest concerning this study.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

12094_2017_1764_MOESM1_ESM.docx (1.6 mb)
Supplementary material 1 (DOCX 1675 kb)

References

  1. 1.
    Bray F, Møller B. Predicting the future burden of cancer. Nat Rev Cancer. 2006;6:63–74. doi: 10.1038/nrc1781.CrossRefPubMedGoogle Scholar
  2. 2.
    Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. Br J Cancer. 1930;2015:1–5. doi: 10.1038/bjc.2014.606.Google Scholar
  3. 3.
    Clèries R, Esteban L, Borràs J, Marcos-Gragera R, Freitas A, Carulla M, et al. Time trends of cancer incidence and mortality in Catalonia during 1993–2007. Clin Transl Oncol. 2014;16:18–28. doi: 10.1007/s12094-013-1060-y.CrossRefPubMedGoogle Scholar
  4. 4.
    Ribes J, Esteban L, Clèries R, Galceran J, Marcos-Gragera R, Gispert R, et al. Cancer incidence and mortality projections up to 2020 in Catalonia by means of Bayesian models. Clin Transl Oncol. 2014;16:714–24. doi: 10.1007/s12094-013-1140-z.CrossRefPubMedGoogle Scholar
  5. 5.
    Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer. 2010;46:1502–13. doi: 10.1016/j.ejca.2010.02.022.CrossRefPubMedGoogle Scholar
  6. 6.
    Clèries R, Buxó M, Martínez JM, Espinàs JA, Dyba T, Borràs JM. Contribution of changes in demography and in the risk factors to the predicted pattern of cancer mortality among Spanish women by 2022. Cancer Epidemiol. 2016;40:113–8. doi: 10.1016/j.canep.2015.12.002.CrossRefPubMedGoogle Scholar
  7. 7.
    Marosi C, Köller M. Challenge of cancer in the elderly. ESMO Open. 2016;. doi: 10.1136/esmoopen-2015-000020.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Antonio M, Saldaña J, Carmona-Bayonas A, Navarro V, Tebé C, Nadal M, Formiga F, Salazar R, Borràs JM. Geriatric assessment predicts survival and competing mortality in elderly patients with early colorectal cancer: can it help in adjuvant therapy decision-making? Oncologist. 2017;22(8):934–43. doi: 10.1634/theoncologist.2016-0462.
  9. 9.
    Clèries R, Martínez JM, Moreno V, Yasui Y, Ribes J, Borràs JM. Predicting the change in breast cancer deaths in Spain by 2019: a Bayesian approach. Epidemiology. 2013;24:454–60. doi: 10.1097/EDE.0b013e31828b0866.CrossRefPubMedGoogle Scholar
  10. 10.
    Clèries R, Ribes J, Buxo M, Ameijide A, Marcos-Gragera R, Galceran J, et al. Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Stat Med. 2012;31:978–87. doi: 10.1002/sim.4463.CrossRefPubMedGoogle Scholar
  11. 11.
    Valls J, Clèries R, Gálvez J, Moreno V, Gispert R, Borràs JM, et al. RiskDiff: a web tool for the analysis of the difference due to risk and demographic factors for incidence or mortality data. BMC Public Health. 2009;9:473. doi: 10.1186/1471-2458-9-473.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    McCormack VA, Boffetta P. Today’s lifestyles, tomorrow’s cancers: trends in lifestyle risk factors for cancer in low- and middle-income countries. Ann Oncol. 2011;22:2349–57. doi: 10.1093/annonc/mdq763.CrossRefPubMedGoogle Scholar
  13. 13.
    Bilal U, Fernández E, Beltran P, Navas-acien A, Bolumar F, Franco M. Validation of a method for reconstructing historical rates of smoking prevalence. Am J Epidemiol. 2014;179:15–9. doi: 10.1093/aje/kwt224.CrossRefPubMedGoogle Scholar
  14. 14.
    Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;2015:1–8. doi: 10.1093/annonc/mdv001.Google Scholar
  15. 15.
    Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;. doi: 10.1007/s12094-016-1607-9.Google Scholar
  16. 16.
    Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92. doi: 10.1016/j.eururo.2012.02.054.CrossRefPubMedGoogle Scholar
  17. 17.
    Binefa G, Rodríguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20:6786–808. doi: 10.3748/wjg.v20.i22.6786.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rossi PG, Vicentini M, Sacchettini C, Di Felice E, Caroli S, Ferrari F, et al. Impact of screening program on incidence of colorectal cancer: a cohort study in Italy. Am J Gastroenterol. 2015;110:1359–66. doi: 10.1038/ajg.2015.240.CrossRefGoogle Scholar
  19. 19.
    Pollán M, Pastor-Barriuso R, Ardanaz E, Argüelles M, Martos C, Galcerán J, et al. Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst. 2009;101:1584–91. doi: 10.1093/jnci/djp358.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403. doi: 10.1016/j.ejca.2012.12.027.CrossRefPubMedGoogle Scholar
  21. 21.
    Bilal U, Beltran P, Fernández E, Navas-Ancien A, Bolumar F, Franco M. Gender equality and smoking: a theory-driven approach to smoking gender differences in Spain. Tob Control. 2016;25:295–300. doi: 10.1136/tobaccocontrol.CrossRefPubMedGoogle Scholar
  22. 22.
    López-Campos JL, Ruiz-Ramos M, Fernandez E, Soriano JB. Recent lung cancer mortality trends in Europe. Eur J Cancer Prev. 2017;. doi: 10.1097/CEJ.0000000000000354 In Press.PubMedGoogle Scholar
  23. 23.
    Hashibe M, Brennan P, Chuang S-C, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomark Prev. 2009;18:541–50. doi: 10.1158/1055-9965.EPI-08-0347.CrossRefGoogle Scholar
  24. 24.
    Syrjänen S. The role of human papillomavirus infection in head and neck cancers. Ann Oncol. 2010;21:243–5. doi: 10.1093/annonc/mdq454.CrossRefGoogle Scholar
  25. 25.
    Torrente MC, Rodrigo JP, Haigentz MJ, Dikkers FG, Rinaldo A, Takes RP, et al. Human papillomavirus infections in laryngeal cancer. Head Neck. 2011;33:581–6. doi: 10.1002/hed.21421.CrossRefPubMedGoogle Scholar
  26. 26.
    Murta-nascimento C, Schmitz-Dräger BJ, Zeegers J, Schmitz-dräger MP, Steineck G, Kogevinas M, et al. Epidemiology of urinary bladder cancer: from tumor development to patient’ s death. World J Urol. 2007;25:285–95. doi: 10.1007/s00345-007-0168-5.CrossRefPubMedGoogle Scholar
  27. 27.
    Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case–Control Consortium (Panc4). Ann Oncol. 2012;23:1880–8. doi: 10.1093/annonc/mdr541.CrossRefPubMedGoogle Scholar
  28. 28.
    Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sanchez MJ, Garau I, et al. Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol 2010; 21. doi: 10.1093/annonc/mdq088.
  29. 29.
    Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331–4. doi: 10.1093/jnci/djj362.CrossRefPubMedGoogle Scholar
  30. 30.
    La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187–95. doi: 10.1002/ijc.29251.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  • R. Clèries
    • 1
    • 2
  • A. Ameijide
    • 3
  • R. Marcos-Gragera
    • 4
    • 5
    • 6
  • L. Pareja
    • 1
  • M. Carulla
    • 3
  • M.-L. Vilardell
    • 4
    • 5
  • L. Esteban
    • 1
  • M. Buxó
    • 7
  • J.-A. Espinàs
    • 1
  • A. Puigdefàbregas
    • 8
  • J. Ribes
    • 1
    • 2
  • A. Izquierdo
    • 4
    • 5
    • 9
  • J. Galceran
    • 3
    • 10
  • J. M. Borrás
    • 1
    • 2
  1. 1.Pla Director d’Oncologia (GENCAT)IDIBELL, Hospital Duran i ReynalsBarcelonaSpain
  2. 2.Departament de Ciències ClíniquesUniversitat de BarcelonaBarcelonaSpain
  3. 3.Registre de Càncer de TarragonaFundació Lliga per a la Investigació i Prevenció del Càncer (FUNCA)-IISPVReusSpain
  4. 4.Unitat d’Epidemiologia i Registre del Càncer de Girona (UERGG)Institut d’Investigació Biomèdica Girona Josep Trueta (IDIBGI)GironaSpain
  5. 5.Institut Català d’Oncologia (ICO)GironaSpain
  6. 6.Departament d’InfermeriaUniversitat de Girona (UdG)GironaSpain
  7. 7.Institut d’Investigació Biomèdica de Girona, IDIBGISaltSpain
  8. 8.Registre de Mortalitat, Direcció General de Planificació en Salut, Departament de SalutGeneralitat de CatalunyaBarcelonaSpain
  9. 9.Departament d’Oncología Médica, Institut Català d’OncologiaHospital Universitari Doctor Josep TruetaGironaSpain
  10. 10.Departament de Medicina i CirurgiaUniversitat Rovira i VirgiliReusSpain

Personalised recommendations